Voloridge Investment Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Voloridge Investment Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-99,642	Closed	-$4.78M	–	1617
2020 Q1	$4.78M	Buy	99,642 +15,642	+19%	+$728K	0.14%	167
2019 Q4	$3.94M	Buy	+84,000	New	+$3.71M	0.08%	332
2019 Q3	–	Sell	-14,207	Closed	-$427K	–	1282
2019 Q2	$427K	Sell	14,207 -13,670	-49%	-$313K	0.01%	592
2019 Q1	$624K	Buy	+27,877	New	+$599K	0.02%	608

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Voloridge Investment Management's RARX Position: Q2 2020 in Review

Voloridge Investment Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 99,642 shares — an estimated $4.78M sold.

Voloridge Investment Management first reported a position in RARX in Q1 2019 and held it in 4 quarters. The position peaked at $4.78M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Voloridge Investment Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Voloridge Investment Management sold 99,642 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $4.78M.
Voloridge Investment Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 4 quarters.
Voloridge Investment Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $4.78M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Voloridge Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.